DCI Mitylene Park is a medicare approved dialysis facility center in Montgomery, Alabama and it has 17 dialysis stations. It is located in Montgomery county at 29 Mitylene Park Lane, Montgomery, AL, 36117. You can reach out to the office of DCI Mitylene Park at (334) 356-2061. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. DCI Mitylene Park has the following ownership type - Non-Profit. It was first certified by medicare in October, 2012. The medicare id for this facility is 012656 and it accepts patients under medicare ESRD program.
| Name | DCI Mitylene Park |
|---|---|
| Location | 29 Mitylene Park Lane, Montgomery, Alabama |
| No. of Dialysis Stations | 17 |
| Medicare ID | 012656 |
| Managed By | Dialysis Clinic, Inc. |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 29 Mitylene Park Lane, Montgomery, Alabama, 36117 | |
| (334) 356-2061 | |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
| NPI Number | 1548527252 |
| Doing Business As | Dialysis Clinic Inc. |
| Address | 29 Mitylene Park Lane Montgomery, Alabama, 36117 |
| Phone Number | (334) 265-9190 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 27 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 59 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 496 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DCI Mitylene Park with elevated calcium levels.
| Patients with hypercalcemia | 60 |
| Hypercalcemia patient months | 504 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 65 |
| Patients with Serumphosphor less than 3.5 mg/dL | 4 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 46 |
| Patient months included in arterial venous fistula and catheter summaries | 350 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 54 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 41 |
| Hospitalization Rate in facility | 93.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 198.5 |
| Hospitalization Rate: Lower Confidence Limit | 46.6 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at DCI Mitylene Park were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 8.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 23.3 |
| Readmission Rate: Lower Confidence Limit | 2 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at DCI Mitylene Park get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.77 (As Expected) |
| SIR: Upper Confidence Limit | 3.68 |
| SIR: Lower Confidence Limit | .72 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether DCI Mitylene Park's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 32 |
| Transfusion Rate in facility | 28 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 97.6 |
| Transfusion Rate: Lower Confidence Limit | 9.4 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at DCI Mitylene Park lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 193 |
| Mortality Rate in facility | 4.7 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 8.6 |
| Mortality Rate: Lower Confidence Limit | 2.3 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago
PCD East Montgomery Location: 6890 Winton Blount Blvd, Montgomery, Alabama, 36117 Phone: (334) 260-0671 |
News Archive
The Johns Hopkins University School of Medicine and the New York Stem Cell Foundation (NYSCF) are establishing a collaborative program to advance the development and use of stem cells in therapies for a wide range of diseases, the organizations announced today. The program will train researchers to use stem cells and foster joint research projects.
Neiker-Tecnalia, the Basque Institute for Agricultural Research and Development, and the company FARMARABA S.L. are working together on a Project designed to produce Omega 3 using marine plant micro-organisms. The ultimate aim is to develop in-house technologies to obtain this highly valued fatty acid, and then apply them at a FARMARABA production plant.
Talk is picking up regarding what exactly 'Perrycare' might look like and how much the nation's health care system will factor into his campaign messages.
Genzyme Corporation announced today that it has received a June 17, 2010 PDUFA date from the FDA for its Biologics License Application for Lumizyme™ (alglucosidase alfa) seeking approval for the therapy produced at the 4000 L scale.
› Verified 3 days ago